Blog
By: Amy Racines, MS, Research & Development Senior Project Coordinator
Tianeptine is an atypical tricyclic antidepressant, commonly referred to as Gas Station Heroin or Za Za. Its use, linked to serious harm and death, has been making headlines. Tianeptine is not approved in the United States but is legal in other countries to treat depression or anxiety. Reports in the United States about severe harm due to tianeptine have been increasing, leading the FDA to issue a formal warning about the drug1.
The clinical effects of tianeptine are very similar to opioids, leading some opioid users to switch to tianeptine as an opioid alternative1. Other users have turned to tianeptine to self-treat depression or anxiety. Tianeptine users experience dependence, withdrawal, and overdose when used at concentrations above the therapeutic doses prescribed in other countries1. However, when tianeptine is used in small doses consistent with therapeutic treatments, no negative side effects have been reported. Several case studies have shown that tianeptine toxicity mimics that experienced from opioids and that naloxone is an effective therapy2,3.
The Centers for Disease Control reports that tianeptine use is on the rise. From 2000 to 2014, there were 11 calls to poison control regarding tianeptine, but from 2014-2017, there were over 200 calls4. Nationally, tianeptine is not scheduled, though Alabama and Michigan have added the drug as a Schedule II substance. Tianeptine is readily available online, typically in tablet or powder form5.
References:
- Tianeptine Products Linked to Serious Harm, Overdoses, Death | FDA
- Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine – PubMed (nih.gov)
- Amitriptyline and tianeptine poisoning treated by naloxone – PubMed (nih.gov)
- Characteristics of Tianeptine Exposures Reported to the National Poison Data System — United States, 2000–2017 | MMWR (cdc.gov)
- Tianeptine (usdoj.gov)
Learn more about Tianeptine Testing at USDTL.
- Forensic vs. Clinical Drug Testing: Why Flexibility Matters for Your Organization
- USDTL’s Integration and Partnership With CourtFact
- New Year, New Capabilities: Offering Forensic & Clinical Testing Options
- Weather Delay
- The Detection of Delta-9-tetrahydrocannabinol, Delta-8-tetrahydrocannabinol, Delta-10-tetrahydrocannabinol, and Cannabidiol in Hair Specimens
- Umbilical Cord Tissue Testing for Ketamine
- Drugs of Abuse: A DEA Resource Guide (2024)
- Beyond THC and CBD: Understanding New Cannabinoids
- February 2026 (1)
- January 2026 (3)
- October 2025 (1)
- July 2025 (3)
- May 2025 (2)
- April 2025 (2)

